NAS:VIVO (USA) Also trade in: Germany UK

Meridian Bioscience Inc

$ 11.58 0.01 (0.09%)
Volume: 221,478 Avg Vol (1m): 372,984
Market Cap $: 493.64 Mil Enterprise Value $: 475.48 Mil
P/E (TTM): 17.77 P/B: 2.76
Earnings Power Value 10.81
Net Current Asset Value 1.68
Tangible Book 2.46
Projected FCF 11.11
Median P/S Value 21.83
Graham Number 6
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7.6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.38
Cash-To-Debt range over the past 10 years
Min: 0.07, Med: 1.06, Max: 10000
Current: 1.38
0.07
10000
Equity-to-Asset 0.72
Equity-to-Asset range over the past 10 years
Min: 0.35, Med: 0.73, Max: 0.92
Current: 0.72
0.35
0.92
Debt-to-Equity 0.26
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.49, Max: 1.41
Current: 0.26
0.01
1.41
Debt-to-EBITDA 1.07
Debt-to-EBITDA range over the past 10 years
Min: 1, Med: 1.18, Max: 1.26
Current: 1.07
1
1.26
Interest Coverage 33.69
Interest Coverage range over the past 10 years
Min: 27.27, Med: 10000, Max: 10000
Current: 33.69
27.27
10000
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.36
DISTRESS
GREY
SAFE
Beneish M-Score -2.49
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 22.92%
WACC 2.28%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 23.75
Operating Margin range over the past 10 years
Min: 20.9, Med: 28.26, Max: 32.9
Current: 23.75
20.9
32.9
Net Margin % 13.29
Net Margin range over the past 10 years
Min: 10.74, Med: 18.32, Max: 22.09
Current: 13.29
10.74
22.09
ROE % 15.51
ROE range over the past 10 years
Min: 12.83, Med: 20.6, Max: 25.54
Current: 15.51
12.83
25.54
ROA % 10.86
ROA range over the past 10 years
Min: 8.59, Med: 18.48, Max: 22.5
Current: 10.86
8.59
22.5
ROC (Joel Greenblatt) % 39.80
ROC (Joel Greenblatt) range over the past 10 years
Min: 35.59, Med: 65.92, Max: 86.08
Current: 39.8
35.59
86.08
3-Year Total Revenue Growth Rate 3.10
3-Year Revenue Growth Rate range over the past 10 years
Min: 0.9, Med: 9.8, Max: 25
Current: 2.5
0.9
25
3-Year Total EBITDA Growth Rate -12.90
N/A
3-Year EPS w/o NRI Growth Rate -13.00
N/A

» VIVO's 30-Y Financials

Financials (Next Earnings Date: 2019-07-30)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:VIVO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Medical Diagnostics & Research    NAICS : 325413    SIC : 2835
Compare SHSE:603716 SZSE:300639 BSP:AALR3 NAS:SRDX HKSE:02393 OHEL:REG1V SZSE:002932 NAS:QTNT SZSE:300289 NAS:OXFD AMEX:SENS BSP:PARD3 NSE:THYROCARE OSTO:IMMNOV NAS:HSKA TSE:2309 XBRU:BCART ASX:IDX NAS:RDNT TSE:4282
Traded in other countries MR4.Germany 0K0K.UK
Address 3471 River Hills Drive, Cincinnati, OH, USA, 45244
Meridian Bioscience Inc develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its diagnostics segment contributes the majority of revenue and manufactures tests primarily for gastrointestinal, viral, respiratory, and parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. Meridian also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. Most of Meridian's revenue comes from North America.

Ratios

Current vs industry vs history
PE Ratio (TTM) 17.77
PE Ratio range over the past 10 years
Min: 16.74, Med: 25.59, Max: 42.17
Current: 17.77
16.74
42.17
Forward PE Ratio 25.71
N/A
PE Ratio without NRI 17.77
PE without NRI range over the past 10 years
Min: 16.74, Med: 25.59, Max: 42.17
Current: 17.77
16.74
42.17
Price-to-Owner-Earnings 14.94
Price-to-Owner-Earnings range over the past 10 years
Min: 14.04, Med: 27.8, Max: 68.13
Current: 14.94
14.04
68.13
PB Ratio 2.76
PB Ratio range over the past 10 years
Min: 2.57, Med: 5.24, Max: 9.32
Current: 2.76
2.57
9.32
PS Ratio 2.40
PS Ratio range over the past 10 years
Min: 2.26, Med: 4.53, Max: 8.73
Current: 2.4
2.26
8.73
Price-to-Free-Cash-Flow 13.16
Price-to-Free-Cash-Flow range over the past 10 years
Min: 12.36, Med: 24.17, Max: 70.85
Current: 13.16
12.36
70.85
Price-to-Operating-Cash-Flow 11.86
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 11.14, Med: 21.46, Max: 48.4
Current: 11.86
11.14
48.4
EV-to-EBIT 12.98
EV-to-EBIT range over the past 10 years
Min: 11.4, Med: 16.1, Max: 27.4
Current: 12.98
11.4
27.4
EV-to-EBITDA 10.64
EV-to-EBITDA range over the past 10 years
Min: 9.9, Med: 14.4, Max: 24
Current: 10.64
9.9
24
EV-to-Revenue 2.28
EV-to-Revenue range over the past 10 years
Min: 2.2, Med: 4.3, Max: 8.4
Current: 2.28
2.2
8.4
Shiller PE Ratio 14.52
Shiller PE Ratio range over the past 10 years
Min: 13.6, Med: 29.88, Max: 95.81
Current: 14.52
13.6
95.81
Current Ratio 6.01
Current Ratio range over the past 10 years
Min: 1.4, Med: 5.5, Max: 11.4
Current: 6.01
1.4
11.4
Quick Ratio 4.31
Quick Ratio range over the past 10 years
Min: 0.87, Med: 3.88, Max: 9.6
Current: 4.31
0.87
9.6
Days Inventory 191.29
Days Inventory range over the past 10 years
Min: 142.17, Med: 181.4, Max: 214.31
Current: 191.29
142.17
214.31
Days Sales Outstanding 58.37
Days Sales Outstanding range over the past 10 years
Min: 44.91, Med: 52.01, Max: 66.42
Current: 58.37
44.91
66.42
Days Payable 35.08
Days Payable range over the past 10 years
Min: 25.32, Med: 33.24, Max: 45.39
Current: 35.08
25.32
45.39

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 3.24
Trailing Dividend Yield range over the past 10 years
Min: 1.78, Med: 3.76, Max: 6.32
Current: 3.24
1.78
6.32
Dividend Payout Ratio 0.78
Dividend Payout Ratio range over the past 10 years
Min: 0.78, Med: 0.95, Max: 1.17
Current: 0.78
0.78
1.17
3-Year Dividend Growth Rate (Per Share) -14.50
N/A
Yield-on-Cost (5-Year) % 2.09
Yield-on-Cost (5y) range over the past 10 years
Min: 1.15, Med: 2.44, Max: 4.1
Current: 2.09
1.15
4.1
3-Year Share Buyback Rate -0.40
3-Year Share Buyback Rate range over the past 10 years
Min: -6.3, Med: -0.7, Max: -0.3
Current: -0.4
-6.3
-0.3

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.71
Price-to-Tangible-Book range over the past 10 years
Min: 1.73, Med: 8.46, Max: 24.67
Current: 4.71
1.73
24.67
Price-to-Projected-FCF 1.04
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.54, Med: 2.41, Max: 6.42
Current: 1.04
0.54
6.42
Price-to-Median-PS-Value 0.53
Price-to-Median-PS-Value range over the past 10 years
Min: 0.14, Med: 0.87, Max: 2.28
Current: 0.53
0.14
2.28
Price-to-Graham-Number 1.93
Price-to-Graham-Number range over the past 10 years
Min: 1.3, Med: 3.22, Max: 6.32
Current: 1.93
1.3
6.32
Earnings Yield (Joel Greenblatt) % 7.71
Earnings Yield (Greenblatt) range over the past 10 years
Min: 3.7, Med: 6.2, Max: 8.8
Current: 7.71
3.7
8.8
Forward Rate of Return (Yacktman) % -2.47
Forward Rate of Return range over the past 10 years
Min: -4.9, Med: 8.2, Max: 23.2
Current: -2.47
-4.9
23.2

More Statistics

Revenue (TTM) (Mil) $ 206.57
EPS (TTM) $ 0.65
Beta 0.12
Volatility % 43.77
52-Week Range $ 10.77 - 19.84
Shares Outstanding (Mil) 42.63

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N